Literature DB >> 30389288

SAR of a new antischistosomal urea carboxylic acid.

Jianbo Wu1, Chunkai Wang1, Cécile Häberli2, Karen L White3, David M Shackleford3, Gong Chen3, Yuxiang Dong1, Susan A Charman3, Jennifer Keiser2, Jonathan L Vennerstrom4.   

Abstract

Urea carboxylic acids, products of aryl hydantoin hydrolysis, were recently identified as a new antischistosomal chemotype. We now describe a baseline structure-activity relationship (SAR) for this compound series. With one exception, analogs of lead urea carboxylic acid 2 were quite polar with Log D7.4 values ranging from -1.9 to 1.8, had high aqueous solubilities in the range of 25-100 µg/mL, and were metabolically stable. None of the compounds had measurable in vitro antischistosomal activity or cytotoxicity, but four of these had moderate worm burden reduction (WBR) values of 42-70% when they were administered as single 100 mg/kg oral doses to S. mansoni-infected mice. These data indicate that with the exception of the gem-dimethyl substructure and the distal nitrogen atom of the urea functional group, the rest of the structure of 2 is required for in vivo antischistosomal activity.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antischistosomal; SAR; Urea carboxylic acid

Mesh:

Substances:

Year:  2018        PMID: 30389288      PMCID: PMC6301076          DOI: 10.1016/j.bmcl.2018.10.039

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

Review 1.  Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery.

Authors:  Aberra Fura; Yue-Zhong Shu; Mingshe Zhu; Ronald L Hanson; Vikram Roongta; W Griffith Humphreys
Journal:  J Med Chem       Date:  2004-08-26       Impact factor: 7.446

2.  Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors.

Authors:  Wenhu Zhan; Yanyang Li; Weiping Huang; Yanjin Zhao; Zhenglin Yao; Shanyou Yu; Shoujun Yuan; Falong Jiang; Shan Yao; Shuxin Li
Journal:  Bioorg Med Chem       Date:  2012-05-30       Impact factor: 3.641

Review 3.  Role of pharmacologically active metabolites in drug discovery and development.

Authors:  Aberra Fura
Journal:  Drug Discov Today       Date:  2006-02       Impact factor: 7.851

Review 4.  In vitro and in vivo trematode models for chemotherapeutic studies.

Authors:  J Keiser
Journal:  Parasitology       Date:  2009-12-07       Impact factor: 3.234

5.  Interactions of mefloquine with praziquantel in the Schistosoma mansoni mouse model and in vitro.

Authors:  Jennifer Keiser; Theresia Manneck; Mireille Vargas
Journal:  J Antimicrob Chemother       Date:  2011-05-20       Impact factor: 5.790

6.  Determination of the dissociation constant of a weak acid using a dissolution rate method.

Authors:  J B Hansen; O Hafliger
Journal:  J Pharm Sci       Date:  1983-04       Impact factor: 3.534

7.  Aryl hydantoin Ro 13-3978, a broad-spectrum antischistosomal.

Authors:  Jennifer Keiser; Gordana Panic; Mireille Vargas; Chunkai Wang; Yuxiang Dong; Nagsen Gautam; Jonathan L Vennerstrom
Journal:  J Antimicrob Chemother       Date:  2015-02-16       Impact factor: 5.790

8.  Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).

Authors:  Chunkai Wang; Qingjie Zhao; Mireille Vargas; Jeremy O Jones; Karen L White; David M Shackleford; Gong Chen; Jessica Saunders; Alice C F Ng; Francis C K Chiu; Yuxiang Dong; Susan A Charman; Jennifer Keiser; Jonathan L Vennerstrom
Journal:  J Med Chem       Date:  2016-11-28       Impact factor: 7.446

  8 in total
  1 in total

Review 1.  Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?

Authors:  Godwin Akpeko Dziwornu; Henrietta Dede Attram; Samuel Gachuhi; Kelly Chibale
Journal:  RSC Med Chem       Date:  2020-04-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.